AstraZeneca Pharma India Ltd. — Earnings Release 2025

Feb 11, 2025

==> picture [503 x 53] intentionally omitted <==

February 11, 2025

The Manager – Listing BSE Limited 1[st] Floor, New Trading Ring Rotunda Building, P J Towers, Dalal Street, Fort, Mumbai 400001

The Manager – Listing National Stock Exchange of India Ltd. Exchange Plaza, 5[th] Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai 400051

Dear Sir(s),

Sub: Press Release

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

Please find enclosed the press release for the unaudited financial results for the quarter and nine months ended December 31, 2024.

Thanking you,

For AstraZeneca Pharma India Limited

Digitally signed MANAS by MANASA RAMA A RAMA Date: 2025.02.11 19:00:52 +05'30'

Manasa. R Company Secretary

==> picture [452 x 64] intentionally omitted <==

News Release

==> picture [112 x 36] intentionally omitted <==

AstraZeneca Pharma India Ltd Q3 Results Highlight Strong Momentum Across Therapeutic Areas; achieving 44% increase in revenue and total revenue from operations now increased by Rs. 1,345 Mn compared to corresponding quarter of previous year.

Bengaluru, February 11, 2025: AstraZeneca Pharma India Limited (the Company), a scienceled biopharmaceutical company, announces its financial results for the third quarter ended December 31, 2024. The Company reported strong financial performance, achieving a 44% increase in revenue compared to the same period last year.

Financial performance Summary

Summary	Summary	Q1 2024 Apr’24- Jun’24 (Value in INR Mn)	Q2 2024 Jul’24-Sep’24 (Value in INR Mn)	Q3 2024 Oct’24- Dec’24 (Value in INR Mn)	YTD Apr’24- Dec’24 (Value in INR Mn)
Total Revenue from Operation		3,875.2	4,080.0	4,402.9	12,358.1
Profit before exceptional item and tax		424.0	510.3	755.7	1,690.0
Profit after exceptional item and tax		(117.9)	384.3	308.5	5,74.9
TA wise performance	Oncology	2,394.2	2,679.7	2,939.0	8,012.9
	Biopharmaceuticals (CVRM, R&I and V&I)	1,263.3	1,180.8	1,209.7	3,653.8
	Rare Disease	2.1	3.3	6.2	11.6

Commenting on the performance, Bhavana Agrawal, Chief Financial Officer & Director of the Company , said, “Our Growth Through Innovation strategy is helping us achieve a robust growth in the country. Our Oncology business last quarter grew by 67%, Biopharmaceutical business grew by 10%, furthering efforts to deliver the next generation of therapeutics in our portfolio and pipeline, and our rare disease business is consistently increasing its focus to help more patients with NF1. Our focus on science and newer access strategies continues to enable us transform health outcomes for patients in the country".

Dr. Sanjeev Panchal, Country President & Managing Director of the Company, said "Our aspiration to be pioneers in science has increased our focus on specialist disease areas where we can make the most meaningful difference in helping people with cancer, other chronic and rare disease. This quarter, we grew by 44% and this consistent progress is a derivative of unwavering commitment to address unmet patient needs while delivering innovative medicines faster to patients in India. We are focused on increasing access to healthcare and making healthcare systems more resilient while contributing sustainably to people, society and the planet.”

News Release

==> picture [112 x 36] intentionally omitted <==

Key milestones:

• Since 2023, the Company has delivered 13 approvals across its portfolio-Oncology, Biopharmaceutical, Rare Disease. Last quarter the Company announced:

• The receipt of permission to import for sale and distribution from the Central Drugs Standard Control Organization, Directorate General of Health, Government of India for the additional indication of Olaparib film coated Tablets 100mg and 150 mg (Lynparza). Through this approval, Olaparib in combination with Durvalumab is indicated for the maintenance treatment of adult patients with advanced or recurrent endometrial cancer whose disease has not progressed on first-line treatment with Durvalumab in combination with platinum-based chemotherapy.

• After the receipt of Import and Market Permission from the Drugs Controller General of India for Budesonide Ph. Eur 160mcg+ Glycopyrronium Ph. Eur 7.2mcg+ Formoterol Fumarate Dihydrate Ph. Eur 5mcg inhalation preparations (Breztri Aerosphere) in the month of December 2023, the Company launched the same in January 2025, which is indicated for the maintenance treatment to relieve symptoms and prevent exacerbations in adult patients with chronic obstructive pulmonary disease (COPD).

• Partnership for Health System Sustainability and Resilience (PHSSR) commissioned independent report was presented at the Embassy of Sweden in the presence of key dignitaries from the Ministry of Health & Family Welfare, key influencers from the healthcare ecosystem followed by a deep deliberation on how private and public sectors need to jointly prioritise areas of concern that emerged from the COVID-19 pandemic and prepare the Indian health system to tackle crises when needed. Read more about PHSSR

Key Appointments

• Mr. Jesus Javier Diaz Ropero Esteso was appointed as an Additional Director of the Company with effect from November 13, 2024

• Ms Amita Bhave was appointed as Head Regulatory Affairs at the Company with effect from November 18, 2024

Recognitions| Q3 ’2024:

• The Company was recognised for a valuable contribution in spreading large scale awareness on RSV in the country at National Neonatology Forum Program - NEOCON 2024

• The Company was awarded a ‘Great Place To Work’ for the seventh consecutive time

• The Company was awarded ‘ET Now Progressive Company of the year’ for demonstrating an exceptional commitment to workplace excellence and contributing significantly to industry success.

News Release

==> picture [112 x 36] intentionally omitted <==

About AstraZeneca Pharma India Ltd

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory & Immunology and Rare Diseases. Established in 1979 in India, it is headquartered at Bengaluru, Karnataka and has a workforce of over 620 employees across the country committed to deliver great medicines to patients through innovative science and global excellence in development and commercialization. For more information, please visit our website: https://www.astrazeneca.in/ or follow us on LinkedIn: AstraZeneca India.